ANN ARBOR, Mich., Oct. 29, 2013 /PRNewswire/ -- NanoBio Corporation today announced that the company has been awarded an initial contract worth $5.5 million from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to develop a nanoemulsion (NE) adjuvant for use with a pandemic influenza vaccine. The total contract is valued at approximately $10.5 million, if all options are exercised.
The funding from NIAID will specifically support the research and development of NanoVax®-Panflu, which combines NanoBio's proprietary NE adjuvant with a plant-based recombinant H5 pandemic influenza antigen. This adjuvanted vaccine has the potential to provide enhanced protection against infection by eliciting both mucosal and systemic immunity. Various research efforts have concluded that achieving mucosal immunity is critical for pathogens that enter the body across mucosal surfaces causing respiratory infections and sexually transmitted diseases.
"Our most recent studies at NanoBio have tested NE-adjuvanted vaccines for respiratory syncytial virus (RSV) and type 2 genital herpes (HSV2), two viruses that enter the body via mucosal sites," said David Peralta, chief executive officer of NanoBio. "The results of these studies very clearly demonstrate the ability of the NE adjuvant to elicit mucosal immunity and the important role this type of immunity plays in protecting against disease."
The award includes a future option to test the NE adjuvant with an HIV vaccine. The vaccine will combine NanoBio's NE adjuvant with recombinant HIV virus-like particles. HIV is a global epidemic; the virus is primarily transmitted through sexual contact. A vaccine that elicits mucosal immunity has the potential to minimize transmission of HIV.
Mr. Peralta added, "With this contract support from NIAID, we will further our studies of the NE adjuvant and its important role in enhancing vaccines against challenging respiratory infections and sexually transmitted diseases. We look forward to moving our NanoVax-Panflu vaccine towards the clinic and on the path to commercialization."
NanoBio's NanoStat® technology platform employs a novel oil-in-water nanoemulsion that can incorporate, deliver and adjuvant multiple antigen types. The NE adjuvant is effective when administered via intranasal, intramuscular or subcutaneous vaccination. In recent studies, NanoBio has demonstrated that intranasal vaccination elicits robust systemic and mucosal immunity, thereby offering enhanced protection against respiratory infections and sexually transmitted diseases compared to intramuscular vaccination.
For additional information, please visit NanoBio.
NanoBio® Corporation is a privately-held biopharmaceutical company focused on developing and commercializing vaccines and anti-infective treatments derived from its patented NanoStat® technology platform. The platform utilizes a novel oil-in-water emulsion adjuvant to enable vaccines that elicit broad protection against disease. The company's headquarters and laboratory facilities are located in Ann Arbor, Michigan. For more information on NanoBio or its products, please visit www.nanobio.com.
SOURCE NanoBio Corporation